The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study

Article (Published Version)

Jauhar, Sameer, Veronese, Mattia, Nour, Matthew M, Rogdaki, Maria, Hathway, Pamela, Natesan, Sridhar, Turkheimer, Federico, Stone, James, Egerton, Alice, McGuire, Philip, Kapur, Shitij and Howes, Oliver D (2019) The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biological Psychiatry, 85 (1). pp. 79-87. ISSN 0006-3223

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/108265/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study

Sameer Jauhar, Mattia Veronese, Matthew M. Nour, Maria Rogdaki, Pamela Hathway, Sridhar Natesan, Federico Turkheimer, James Stone, Alice Egerton, Philip McGuire, Shitij Kapur, and Oliver D. Howes

ABSTRACT
BACKGROUND: Elevated striatal dopamine synthesis capacity has been implicated in the etiology and antipsychotic response in psychotic illness. The effects of antipsychotic medication on dopamine synthesis capacity are poorly understood, and no prospective studies have examined this question in a solely first-episode psychosis sample. Furthermore, it is unknown whether antipsychotic efficacy is linked to reductions in dopamine synthesis capacity. We conducted a prospective [18F]-dihydroxyphenyl-L-alanine positron emission tomography study in antipsychotic naïve/free people with first-episode psychosis commencing antipsychotic treatment.

METHODS: Dopamine synthesis capacity (indexed as influx rate constant) and clinical symptoms (measured using Positive and Negative Syndrome Scale) were measured before and after at least 5 weeks of antipsychotic treatment in people with first-episode psychosis. Data from a prior study indicated that a sample size of 13 would have >80% power to detect a statistically significant change in dopamine synthesis capacity at alpha = .05 (two tailed).

RESULTS: A total of 20 people took part in the study, 17 of whom were concordant with antipsychotic medication at therapeutic doses. There was no significant effect of treatment on dopamine synthesis capacity in the whole striatum (p = .47), thalamus, or midbrain, nor was there any significant relationship between change in dopamine synthesis capacity and change in positive (r = .35, p = .13), negative, or total psychotic symptoms.

CONCLUSIONS: Dopamine synthesis capacity is unaltered by antipsychotic treatment, and therapeutic effects are not mediated by changes in this aspect of dopaminergic function.

Keywords: Antipsychotic drugs, Dopamine, F-DOPA, Positron emission tomography, Psychosis, Schizophrenia

https://doi.org/10.1016/j.biopsych.2018.07.003
of dopamine neurons in substantia nigra and ventral tegmental area (22). The effects of antipsychotics on dopamine neuron firing have also been tested in a neurodevelopmental animal model of schizophrenia (the methylazoxymethanol acetate model) that shows increased population activity of midbrain dopamine neurons. This study showed that depolarization blockade is induced more rapidly in these animals than in wild-type animals (23), suggesting that depolarization blockade may be more rapid in a hyperdopaminergic state. This contrasts with findings from an animal study using microdialysis, which showed no effect of chronic haloperidol treatment on striatal levels of extracellular dopamine and its metabolites (24).

To date, only one study has examined effects of subchronic antipsychotic treatment in people with psychosis. Gründer et al. found decreased [18F]-DOPA uptake (k3) in striatum and thalamus in 9 antipsychotic-free people with schizophrenia treated with haloperidol (25). That study also found that greater improvement in negative symptoms, but not positive symptoms, was associated with greater reduction in thalamic [18F]-DOPA uptake. This suggests that reduction in dopamine synthesis capacity may be related to symptom change. However, the study by Gründer et al. used haloperidol, a first-generation antipsychotic, at relatively high doses (mean dose of 8.9 mg/day)—a dose that would be expected to result in D2/3 occupancy >90% in first-episode patients (17), which might explain effects on the dopamine system. Modern clinical practice, however, involves treatment with second-generation antipsychotics at lower relative doses, which would be expected to have lower D2/3 occupancy (26). It therefore remains unknown whether antipsychotic treatment with second-generation antipsychotics at doses reflecting current practice decreases striatal dopamine synthesis capacity and whether this has any relationship to symptom change.

Therefore, we sought to examine the effect of antipsychotic medication on striatal dopamine synthesis capacity in people experiencing their first episode of psychotic illness and its relationship to symptom change.

We tested the following hypotheses: 1) There would be a decrease in striatal dopamine synthesis capacity with antipsychotic treatment; and 2) Reduction in striatal dopamine synthesis capacity would be directly associated with reduction in positive psychotic symptoms, and reduction in thalamic dopamine synthesis capacity would be directly associated with negative psychotic symptom change.

An exploratory analysis of associative striatum baseline KiFer and symptomatic response was also conducted based on a prior cross-sectional study suggesting a relationship between this striatal subdivision and antipsychotic response (27).

METHODS AND MATERIALS

Ethical permission was obtained from the East of England–Cambridge East Ethics Committee and the Administration of Radioactive Substances Advisory Committee. All participants provided informed written consent to participate.

Participants

Patients were recruited from first-episode psychosis services in London. Inclusion criteria were diagnosis of a psychotic disorder according to ICD-10 criteria (28), fulfilling criteria for having a first episode of psychosis (29), requiring treatment with antipsychotic medication, and being antipsychotic naïve or antipsychotic free for at least 6 weeks [other clinical studies in similar populations require being antipsychotic free for a minimum of 3 weeks (30,31)].

For comparison, a matched sample of healthy control subjects was included. Inclusion criteria included no psychiatric morbidity, as assessed by the Mini-International Neuropsychiatric Interview (32), and no contraindications to PET scanning, as per the patient sample.

Exclusion criteria for all subjects were history of significant head trauma, dependence on illicit substances or alcohol, medical comorbidity (other than minor illnesses), use of sodium valproate [owing to effects on dopamine synthesis capacity (33)], and contraindications to scanning (such as pregnancy).

Tobacco smoking was not an exclusion criterion.

Clinical Measures

The following clinical measures were rated at baseline and at least 5 weeks after antipsychotic initiation: Positive and Negative Syndrome Scale (PANSS) (34), Global Assessment of Functioning (35), and Clinical Global Impression—Improvement scale (CGI-I) (36). Response status (dichotomized as responder vs. nonresponder) was measured, in keeping with prior PET studies, based on a rating of much improved or very much improved on CGI-I (17).

Baseline

People presenting with first-episode psychosis received one baseline [18F]-DOPA scan prior to initiation of antipsychotic medication. They were classified as antipsychotic naïve or medication free (free of oral antipsychotic medication for 6 weeks or longer).

Treatment

Because this was a naturalistic study, antipsychotic treatment was decided by the treating clinician and patient. All doses were required to be within the therapeutic range for the drug defined in the Maudsley Prescribing Guidelines (36). Use of other psychotropic medication (such as antidepressants and benzodiazepines) was permitted, although use of sodium valproate was not (because it may have effects on [18F]-DOPA uptake (33)). To assess concordance with antipsychotic medication, we used a multisource approach, requiring evidence of adequate adherence on at least two of the following: antipsychotic plasma levels, pharmacy and electronic medical dispensing records, and report from the patient and an independent source (family member/caregiver or health care professional). Adequate concordance was defined as taking a minimum of 80% of prescribed doses, in line with consensus recommendations (37). To measure antipsychotic exposure, we determined chlorpromazine-equivalent dose years, calculated as described by Andreasen et al. (38). [In the cases of lurasidone and amisulpride, we used the method described by Leucht et al. (39), using data from the Maudsley Prescribing Guidelines, because these are not covered by Andreasen et al.].
Effects of Antipsychotics on Dopamine Function in Psychosis

Follow-up
All participants received follow-up [18F]-DOPA scans and clinical measures (PANSS, Global Assessment of Functioning, and CGI-I) after at least 5 weeks of antipsychotic treatment at an adequate dose as defined in the Maudsley Prescribing Guidelines and meeting concordance criteria described above. Clinical follow-up was conducted 6 months after the baseline scan to confirm diagnosis using the Mini-International Neuropsychiatric Interview.

[18F]-DOPA PET Imaging
All participants were asked not to eat or drink (except water) and to refrain from alcohol for 12 hours prior to scan. Cigarette smokers were not permitted to smoke during the 4 hours preceding the scan. The 4-hour cutoff for last cigarette smoked in this study was based on evidence that nicotine’s occupancy of the acetylcholine nicotinic receptor does not change appreciably between 2 and 5 hours after last administration of nicotine (40).

Imaging data were obtained on a Siemens Biograph 6 HiRez PET scanner (Siemens, Erlangen, Germany) in three-dimensional mode. One hour before scanning, participants received 400 mg of entacapone, a peripheral catechol-o-methyl-transferase inhibitor, and 150 mg of carbidopa, a peripheral aromatic acid decarboxylase inhibitor, to prevent formation of radiolabeled metabolites that may cross the blood-brain barrier (41). Participants were positioned in the scanner with the orbitomeatal line parallel to the transaxial plane of the tomograph. Head position was marked and monitored, and movement was minimized using a head strap. After acquiring a computed tomography scan for attenuation correction, [18F]-DOPA was administered by bolus intravenous injection 30 seconds after start of PET imaging. PET data were acquired in 32 frames of increasing duration over the 95-minute scan (frame intervals: 8 × 15 seconds, 3 × 60 seconds, 5 × 120 seconds, 16 × 300 seconds).

The region-of-interest analysis was conducted blind to medication status. Our primary end point was striatal influx constant (Kf) for the whole striatum. For each participant, we calculated Kf for bilateral whole striatum, caudate, putamen, and thalamus in light of prior work by Gründer et al. (25). Whole striatum was chosen instead of striatal functional subdivisions (such as associative striatum) given lack of prior investigation of striatal subdivisions and antipsychotic effects. Secondary analyses were also conducted with substantia nigra, given prior findings of a relationship between psychotic symptoms and dopamine synthesis capacity in substantia nigra (15), and with associative striatum and treatment response, based on prior literature (27).

Correction for head movement during scan was performed by employing a mutual information algorithm (42). SPM8 (43) was used to automatically normalize a tracer-specific [18F]-DOPA template (44) together with the striatal brain atlas as defined by Martinez et al. (45) and the Hammersmith brain atlas (46). The Hammersmith brain atlas was used to identify extrastriatal regions and reference region (cerebellum). The region-of-interest atlas was transformed into the subject’s PET space using the tracer-specific template without using co-registered magnetic resonance imaging. This method showed good reliability in a previous test–retest study (47).

Kf was calculated using the Patlak–Gjedde graphical approach adapted for a reference tissue input function (48). Further details of the image analysis approach are given in prior publications (16,49). Although our reference region approach is robust to global differences in radiotracer delivery to the brain (50,51), we examined the reference region (cerebellum) to ascertain change in standardized uptake value in cerebellum at 95 minutes. To exclude potential effects of weight, we conducted correlation analysis of weight and Kf for participants at baseline.

Striatal volume measures were derived from the atlas-based segmentation as the number of voxels in the striatal region multiplied by the volume of a single PET image voxel (voxel volume = 2.05 mm × 2.05 mm × 2 mm = 8.41 mm3). This analysis was undertaken to investigate whether there was a change in striatal volume over time.

Statistical Analysis
Statistical analyses were performed using SPSS Version 23 (IBM Corp., Armonk, NY), and significance was set at p < .05 (two tailed). Normality of distribution for dopamine synthesis capacity (Kf), PANSS ratings, and changes in all these measures was assessed using the Shapiro–Wilks test. To test hypothesis 1 (change in Kf with antipsychotic medication) and changes in clinical variables over follow-up, we used paired sample t tests. The data from Gründer et al. (25) indicated that a sample size of 13 would have >80% power to detect a statistically significant change in dopamine synthesis capacity at alpha = .05 (two tailed).

To test hypothesis 2 (relationship between change in Kf and change in PANSS symptoms scores), we used Pearson’s correlation coefficients for normally distributed data and Spearman’s correlation coefficients for non-normally distributed data. Because hypothesis 2 related to the relationship between dopamine synthesis capacity and symptom change irrespective of treatment (examining possible state effects), all subjects who took part in the study were included (including those non-concordant with antipsychotic medication and those receiving inadequate antipsychotic treatment) in the primary analysis. We then conducted a further exploratory analysis to determine whether correlations between dopamine synthesis capacity and symptom change were seen in patients who met full adherence criteria to test specificity to antipsychotic treatment.

Change in clinical symptom scales was measured by calculating percentage change in PANSS score, accounting for minimum scores (7 for positive and negative symptoms and 30 for total symptoms) as shown here for the PANSS positive symptom subscale:

\[ \text{% change in positive PANSS} = \frac{((\text{baseline score} - 7) - (\text{follow-up score} - 7)) \times 100}{(\text{baseline score} - 7)} \]

Change in dopamine synthesis capacity (DSC) was calculated as follows:

\[ \text{Change in DSC} = \frac{\text{DSC}_{\text{baseline}} - \text{DSC}_{\text{follow-up}}}{\text{DSC}_{\text{baseline}}} \times 100 \]
RESULTS
A total of 20 patients completed the study and received two \(^{18}\)F-DOPA scans. Of these, 15 were antipsychotic naïve and 5 were medication free at time of scanning (previously receiving antipsychotic medication and being medication free for 6 weeks or longer). Of these patients, 3 did not meet the criteria for adequate treatment prior to the follow-up scan (1 patient was treated with a subtherapeutic dose of antipsychotic medication because that patient declined to take higher doses, and 2 patients were nonconcordant).

Therefore, we excluded these 3 patients, leaving 17 patients to test hypothesis 1 (change in \(K_{i\text{cer}}\) after antipsychotic treatment).

All 20 patients were included to test hypothesis 2 (relationship between change in \(K_{i\text{cer}}\) and change in symptoms) because this was not dependent on antipsychotic treatment. Demographic and clinical details are given in Table 1. Details of antipsychotic treatment that patients received after baseline scan are given in Supplemental Table S1.

Median time between scans was 71 days (interquartile range of 125 days).

No relationship was found between time between PET scans and change in \(K_{i\text{cer}}\) \((r = -0.03, p = 0.92)\).

Of the 20 patients recruited in total, 12 met criteria for schizophrenia and 8 for bipolar affective disorder at 6-month follow-up.

There was a statistically significant elevation in whole striatal \(K_{i\text{cer}}\) in patients compared with control subjects \((t_{53} = 2.32, p = 0.03, \text{two tailed})\) (control subjects mean = 12.41 × 10\(^{-3}\)/min, SD = 1.11 × 10\(^{-3}\)/min).

Data on the baseline scans for 18 patients reported here have been published in Jauhar et al. (16) and Jauhar et al. (52). None of the follow-up scans have been previously reported.

The latter study analyzed baseline \(K_{i\text{cer}}\) in a larger group of first-episode psychosis patients \((n = 26)\). The 8 additional subjects did not receive follow-up F-DOPA PET scans.

Antipsychotic Treatment
Two patients started on an antipsychotic but discontinued it owing to side effects and switched to another antipsychotic that they then received at an adequate dose and duration prior to follow-up scan. Where this occurred, the discontinued medication is noted first, followed by the drug they then received. Three patients took low-dose aripiprazole to prevent weight gain and hyperprolactinemia in addition to the main antipsychotic. Where this occurred, the main antipsychotic is noted first, followed by aripiprazole to indicate its use as an adjunct. Regarding adjunctive medication, 1 patient was taking sertraline (150 mg) at initial scan, which was unchanged at follow-up.

There was a significant reduction in all symptoms following treatment (Table 2).

Baseline \(K_{i\text{cer}}\) and Change in PANSS
There was a significant positive relationship between baseline associative striatum \(K_{i\text{cer}}\) and change in positive symptoms \((r = 0.52, p = 0.03)\).

There was a significant positive relationship between baseline associative striatum \(K_{i\text{cer}}\) and change in total symptoms \((r = 0.49, p = 0.045)\).

There was a trend for an association between whole striatum \(K_{i\text{cer}}\) and change in positive symptoms \((r = 0.48, p = 0.05)\).

There was no association between whole striatum \(K_{i\text{cer}}\) and change in total symptoms \((r = 0.46, p = 0.06)\).

There was no association between whole striatum \(K_{i\text{cer}}\) and change in negative symptoms (Spearman’s \(r = 0.37, p = 0.14)\).

Change in Dopamine Synthesis Capacity With Antipsychotic Medication
Median antipsychotic treatment received was 0.38 chlorpromazine dose years (interquartile range of 0.41). There was no significant change in whole striatal dopamine synthesis capacity (\(K_{i\text{cer}}\)) in people who received adequate treatment (baseline mean = 13.07 × 10\(^{-3}\)/min, SD = 1.01 × 10\(^{-3}\)/min; follow-up mean = 12.85 × 10\(^{-3}\)/min, SD = 1.09 × 10\(^{-3}\)/min), \(t_{16} = 0.74, p = 0.47\) (Figure 1).

Data points for all subjects are given as a scatter plot in Supplemental Figure S1, categorized as responders, non-responders (using CGI-I), and subjects taking subtherapeutic medication and those nonconcordant with antipsychotic medication.

Because aripiprazole is a partial agonist, in contrast to a full antagonist, and thus may have different effects, we

| Variable | PET Sample Adherent to Treatment \((n = 17)\) | PET Sample Including Nonadherent or Partially Adherent Patients \((n = 20)\) | Control Sample \((n = 20)\) |
|----------|---------------------------------------------|-------------------------------------------------|-----------------|
| Age, Years, Mean (SD) | 24.00 (2.87) | 24.55 (3.36) | 24.55 (3.99) |
| Male Subjects (%) | 15 (88) | 17 (85) | 18 (90) |
| Ethnicity of Subjects (%) | White, \(n = 6\) (35) | White, \(n = 8\) (40) | White, \(n = 10\) (50) |
| | Black, \(n = 5\) (29) | Black, \(n = 6\) (30) | Black, \(n = 6\) (30) |
| | Asian, \(n = 2\) (12) | Asian, \(n = 2\) (10) | Asian, \(n = 1\) (5) |
| | Mixed, \(n = 4\) (24) | Mixed, \(n = 4\) (20) | Mixed, \(n = 3\) (15) |
| Smoking Status (%) | Current smoker, \(n = 9\) (53) | Current smoker, \(n = 10\) (50) | Current smoker, \(n = 8\) (40) |
| | Past smoker, \(n = 3\) (18) | Past smoker, \(n = 3\) (15) | Past smoker, \(n = 3\) (15) |
| | Nonsmoker, \(n = 5\) (29) | Nonsmoker, \(n = 7\) (35) | Nonsmoker, \(n = 9\) (45) |
| Medication Status at Baseline | Antipsychotic naïve, \(n = 12\) | Antipsychotic naïve, \(n = 15\) | N/A |
| | Antipsychotic free, \(n = 5\) | Antipsychotic free, \(n = 5\) | |

N/A, not applicable; PET, positron emission tomography.
repeated the analyses after excluding the 2 subjects who received aripiprazole monotherapy and repeated the analysis after excluding all subjects taking aripiprazole, including those taking it as an adjunct to a dopamine antagonist. There was no significant effect of antipsychotic treatment on Ki<sup>cer</sup> after restricting the analyses to subjects taking full antagonists in either analysis (p = .40 and p = .91, respectively).

There was no significant effect of treatment on K<sub>cer</sub><sup>i</sup> for the other regions analyzed (striatal functional subdivisions, caudate, putamen, thalamus, and substantia nigra) (see Table 3).

There was no change in standardized uptake value in the reference region (cerebellum) with treatment (baseline mean = 1.3 × 10<sup>−3</sup>/min, SD = 0.35 × 10<sup>−3</sup>/min; follow-up mean = 1.45 × 10<sup>−3</sup>/min, SD = 0.58 × 10<sup>−3</sup>/min), t<sub>16</sub> = −1.27, p = .15. There was no change in striatal volume before and after antipsychotic treatment (baseline mean = 2006.53 mm<sup>3</sup>, SD = 180.54) and follow-up (mean = 2047.94 mm<sup>3</sup>, SD = 216.43), t<sub>16</sub> = −1.39, p = .18. There was no effect of weight on K<sub>cer</sub><sup>i</sup> (r = .08, p = .73).

**Relationship Between Change in Dopamine Synthesis Capacity and Symptom Change**

There was no significant correlation between percentage decrease in whole striatal K<sub>cer</sub><sup>i</sup> and percentage improvement in PANSS positive symptoms (n = 20, p = .35, p = .13), total symptoms (p = .25, p = .29), or negative symptoms (p = .10, p = .68) (see Figure 2).

There was no relationship between change in thalamic Ki<sup>cer</sup> and change in PANSS negative symptom severity score in people taking antipsychotic treatment (n = 17, p = .26, p = .31).

**DISCUSSION**

Our main findings were that there was no significant change in striatal dopamine synthesis capacity with antipsychotic treatment and no significant association between change in dopamine synthesis capacity and change in psychotic symptoms. To the best of our knowledge, this is the first study to measure change in dopamine synthesis capacity after treatment with second-generation antipsychotics.

**Effects of Antipsychotic Medication on Presynaptic Dopamine Function**

Our finding of no change in presynaptic striatal dopamine function with prolonged antipsychotic treatment is consistent with acute studies in healthy volunteers, which found no significant overall change in dopamine synthesis capacity after treatment with a number of different antipsychotic drugs (53–55). However, our findings contrast with those in the only other study examining effects in a markedly smaller sample of people with schizophrenia (25), which found a decrease in dopamine synthesis capacity in caudate and putamen after a mean of 5 weeks haloperidol treatment. A possible explanation could be the relatively high dose of haloperidol (nearly double the chlorpromazine-equivalent dose in our study). Thus, taken together with our findings, this suggests that while higher doses of antipsychotics may have effects, antipsychotic treatment at doses in the range typically used in current practice is not associated with significant changes in dopamine synthesis capacity.

Our study differed from the Gründer et al. (25) study in terms of experimental design and methodology for quantification of F-DOPA kinetics and therefore is not directly comparable. From a methodological perspective, the two parameters of interest (k<sub>3</sub> in the Gründer et al. study and K<sub>cer</sub><sup>i</sup> in our study) are different. K<sub>cer</sub><sup>i</sup> is related to k<sub>3</sub> and K<sub>cer</sub><sup>i</sup> in our study (56) but also is dependent on perfusion and tissue-to-blood tracer diffusion. One major methodological difference is the length of scan (120 minutes in the Gründer et al. study vs. 95 minutes in our study). There is evidence from monkey and human studies that metabolism of radiolabeled dopamine becomes...
appreciable by 120 minutes (57,58). Because dopamine metabolism is not accounted for in the analysis used by Gründer et al. (25), this could introduce noise into the measurement of Kicer.

It is also worth noting that Gründer et al. (25) found, after haloperidol, an increase in absolute terms of radiolabeled DOPA volume of distribution and reduction in radiolabeled DOPA from striatal tissue back across the blood-brain barrier. We did not measure these parameters, although we would expect alterations in them to alter Kicer if antipsychotic treatment had altered them in our study, so this is unlikely to explain our findings.

Microdialysis findings show that antipsychotic treatment acutely induces a transient increase in striatal extracellular dopamine levels, which fall back to basal levels with chronic treatment (24). Our results are consistent with these findings and extend them to show that, in addition to having no lasting effect on extracellular dopamine levels, chronic treatment does not alter dopamine synthesis capacity. It should be recognized that we did not measure dopamine neuron firing, and so our findings cannot exclude an effect on midbrain dopamine neuron firing, as seen in the electrophysiology studies of chronic antipsychotic treatment (29). Determining this will require preclinical studies to test the relationship among dopamine neuron firing, striatal dopamine levels, and dopamine synthesis capacity.

We did not find a change in striatal volume with antipsychotics in our study. A systematic review of the effects of second-generation antipsychotics, such as those used in our study, found inconsistent effects on striatal volume, with some studies reporting increases, others finding decreases, and others finding no effects, as was the case in our study (59).

**Limitations**

Our study was powered to detect a statistically significant difference and relationship between change in symptoms and change in dopamine synthesis capacity of the size reported by Gründer et al. (25). While a type II error remains possible, the data suggest that any effect is unlikely to be clinically significant. It should be acknowledged that the follow-up at 6 months showed that the patient group included patients who subsequently met diagnostic criteria for bipolar affective disorder as well as schizophrenia. It is often not possible to disentangle diagnoses at baseline, although we should emphasize that criteria for study entry included the presence of psychosis, according to criteria used before to define psychosis in first-episode illness (60) and requiring antipsychotic treatment (61).

Because our study was naturalistic in design, we were unable to test the effects of one specific antipsychotic and accept that some antipsychotics used in this study (e.g., amisulpride) have more selectivity for D2/3 receptors. Nonetheless, by focusing on antipsychotic response and including only people taking antipsychotics at a dose that would block D2/3 receptors, we examined a potential common mechanism by which antipsychotics might act.

It should be noted that 4 hours after smoking a cigarette could correspond to the period of subjective nicotine withdrawal, although nicotine’s occupancy of nicotinic receptors in the brain remains high (40).

It is conceivable that antipsychotics could have had an effect on blood flow (62) and effects on tracer delivery to the reference region (cerebellum). Our finding of no difference in standardized uptake value in the cerebellum suggests that this is not a significant issue, although further studies are required to exclude this and investigate local blood flow changes. Moreover, it is unlikely to account for our findings given that this would require opposite blood flow effects in the cerebellum to the striatum to account for no overall change. Ideally, tests of the biological effect of antipsychotic drugs would involve randomizing patients to placebo treatment as well as...
Effects of Antipsychotics on Dopamine Function in Psychosis

excluding nonspecific effects of treatment. This would have ethical implications and therefore is unlikely to be feasible.

Implications for Clinical Care

Our main finding, that antipsychotics do not alter dopamine synthesis capacity in people with first-episode psychosis, extends cross-sectional evidence that dopamine synthesis capacity remains elevated, even in patients on long-term antipsychotic treatment (12,63), to indicate that antipsychotics do not normalize the major (presynaptic) dopaminergic abnormality seen in the disorder. This provides a potential neurobiological explanation for why psychosis recurs after antipsychotic treatment is stopped (64) and, potentially for continued treatment, suggests that stopping dopamine receptor blockade would lead to dopamine dysfunction’s being unmasked.

In conclusion, antipsychotic medication does not alter dopamine synthesis capacity in people with first-episode psychosis, and change in symptoms is not associated with change in dopamine synthesis capacity. This indicates that therapeutic effects of antipsychotic medication are not due to altering dopamine synthesis capacity.

ACKNOWLEDGMENTS AND DISCLOSURES

This study was funded by Medical Research Council Grant No. MC-A656-50D30, Maudsley Charity Grant No. 66, support from the U.S. Brain & Behavior Research Foundation, and Wellcome Trust Grant No. 094849/Z/05/QD30, Maudsley Charity Grant No. 66, support from the U.S. Brain & Intervention Services in South and West London who facilitated this study, and funding by a JMAS (John, Margaret, Alfred, and Stewart) Sim Fellowship from the Royal College of Physicians, Edinburgh.

We thank Drs. N. Rahaman and P.D. Morrison and staff within Early Intervention Services in South and West London who facilitated this research.

ODH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by AstraZeneca, Autifony, Bristol-Myers Squibb, Eli Lilly, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand, and Roche. Neither ODH nor his family has been employed by or have holdings or a financial stake in any biomedical company. SK has received grant support from AstraZeneca and GlaxoSmithKline and has served as consultant and/or speaker for AstraZeneca, Bioline, Bristol-Myers Squibb–Otsuka, Eli Lilly, Janssen (Johnson & Johnson), Lundbeck, NeuroSearch, Pfizer, Roche, Servier, and Solvay Wyeth. PM reports receiving investigator-initiated research funding from or participating in advisory or speaker meetings organized by Sunovion, Janssen, GW Pharmaceuticals, Takeda, and Roche. JS reports no disclosure relating to schizophrenia research, although he has received honorarium for advisory work with Janssen, SJ, MV, MMN, MR, PH, SN, FT, and AE report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Department of Psychological Medicine (SJ), Centre for Neuroimaging Sciences (MV, FT, JS), and Psychiatry Studies (MMN, MR, PH, SN, JS, AE, PM, ODH), Institute of Psychiatry, Psychology and Neuroscience, King’s College London; Early Intervention Psychosis Clinical Academic Group (SJ, PM), South London and Maudsley NHS Trust; Psychiatric Imaging Group (MR, ODH), MRC London Institute of Medical Sciences, and Institute of Clinical Sciences (ODH), Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom; and Faculty of Medicine, Dentistry and Health Sciences (SK), University of Melbourne, Parkville, Victoria, Australia.

Address correspondence to Oliver Howes, Ph.D., Po 67 Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Camberwell, London SE5 8AF, UK; E-mail: Oliver.howes@kcl.ac.uk.

Received Apr 1, 2018; revised Jul 2, 2018; accepted Jul 3, 2018.

Supplemental material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2018.07.003.

REFERENCES

1. Howes OD, Murray RM (2014): Schizophrenia: An integrated sociodevelopmental–cognitive model. Lancet 383:1677–1687.
2. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012): Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379:2063–2071.
3. Lally J, Afnakina O, Forti MD, Trotta A, Demjaha A, Kollakou A, et al. (2016): Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 46:3231–3240.
4. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher–Svanum H, Kollack-Walker S, et al. (2011): Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187:42–48.
5. Carbon M, Correll CU (2014): Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 16:505–524.
6. Leucht S, Cipriani A, Spinelli L, Mavridis D, Orey D, Richter F, et al. (2013): Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382:951–962.
7. Howes OD, Kapur S (2014): A neurobiological hypothesis for the classification of schizophrenia: Type A (hypodopaminergic) and Type B (normodopaminergic). Br J Psychiatry 205:1–3.
8. van Rossum JM (1966): The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492–494.
9. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: A review and conceptualization. Am J Psychiatry 148:1474–1486.
10. Meltzer HY, Stahl SM (1976): The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2:19–76.
11. Howes OD, Kapur S (2009): The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophr Bull 35:549–562.
12. Howes OD, Kambeitz J, Kim E, Stahl D, Silfstein M, Abi-Dargham A, Kapur S (2012): The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Arch Gen Psychiatry 69:776–786.
13. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. (2011): Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol Psychiatry 16:885–896.
14. Laruelle M, Abi-Dargham A (1999): Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 13:358–371.
15. Howes OD, Williams M, Iibrani K, Leung G, Egerton A, McGuire PK, Turkheimer F (2013): Midbrain dopamine function in schizophrenia and depression: A post-mortem and postmortem emission tomographic imaging study. Brain 136:3242–3251.
16. Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. (2017): A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 74:1206–1213.
17. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000): Relations between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520.
18. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoef NP, Kerwin RW (1993): Antipsychotic medication, D2 dopamine receptor blockade and...
clinical response: A \textsuperscript{123}I IBZM SPET (single photon emission tomography) study. Psychol Med 23:791–797.

19. Wolkin A, Barouche F, Wolf AP, Rotrofen J, Fosler JS, Shiue CY, et al. (1989): Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908.

20. Grace AA, Bunney BS, Moore H, Todd CL (1997): Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31–37.

21. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715–1727.

22. White FJ, Wang RY (1984): A10 dopamine neurons: Role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci 34:1161–1170.

23. Valenti O, Cifelli P, Gill KM, Grace AA (2011): Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci 31:12330–12338.

24. Samaha A-N, Seeman P, Stewart J, Rajabi H, Kapur S (2007): “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979–2986.

25. Gründler G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz H-G, et al. (2003): Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28:787–794.

26. Mamo D, Kapur S, Shami M, Papapetrou G, Mann S, Themien F, Remington G (2004): A PET study of dopamine D\textsubscript{2} and serotonin 5-HT\textsubscript{1A} receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818–825.

27. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012): Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169:1203–1210.

28. World Health Organization (1992): The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.

29. Breitborde NJK, Srihari VH, Woods SW (2009): Review of the operational definition for first-episode psychosis. Early Interv Psychiatry 3:259–265.

30. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Valenti O, Cifelli P, Gill KM, Grace AA (1997): Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908.

31. Thompson JL, Urban N, Silfsten M, Xu X, Kegels LS, Girgis RR, et al. (2013): Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 18:909–915.

32. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998): The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33.

33. Yatham LN, Liddle PF, Shah I-S, Lam RW, Nagan E, Scarow G, et al. (2002): PET study of \textsuperscript{11}C fluorodopa in neuroleptic-naive first-episode nonpsychotic mania: Effects of treatment with divalproex sodium. Am J Psychiatry 159:788–774.

34. Kay SR, Fiszbein A, Opfer LA (1998): The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–267.

35. Jones SH, Thomsen C, Coffey M, Dunn G (1999): A brief mental health outcome scale—Reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654–659.

36. Busner J, Targum SD (2007): The Clinical Global Impressions Scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28–37.

37. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. (2016): Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216–229.

38. Andreasen NC, Plessner M, Nopoulos P, Miller D, Ho B-C (2010): Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry 67:255–262.

39. Leucht S, Samara M, Heres S, Patel MK, Woods SW, Davis JM (2014): Dose equivalents for second-generation antipsychotics: The minimum effective dose method. Schizophr Bull 40:314–326.

40. Esterlis I, Mitsis EM, Batsis JC, Bois F, Picciotto MR, Stiklia SM, et al. (2011): Brain \textsuperscript{15}O-nicotine acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol 14:389–398.

41. Cuming P, Léger GC, Kucwabara H, Gjedde A (1993): Pharmacokinetics of plasma \textsuperscript{6}-\textsuperscript{11}Cfluoroo-L-3,4-dihydroxyphenylalanine (\textsuperscript{11}C FDopa) in humans. J Cereb Blood Flow Metab 13:668–675.

42. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ (1999): Multi-resolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 19:1189–1208.

43. Wellcome Trust Centre for Neuroimaging, Statistical Parametric Mapping Available at: http://www.fil.ion.ucl.ac.uk/spm. Accessed October 28, 2016.

44. Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Valli I, Tabraham P, et al. (2009): Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13–20.

45. Martinez D, Narendran R, Foltin RW, Silfsten M, Hwang D-R, Broff A, et al. (2007): Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622–629.

46. Hammers A, Alom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. (2003): Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19:224–247.

47. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD (2010): The test–retest reliability of \textsuperscript{18}F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 50:524–531.

48. Paltiak CS, Blasberg RG (1985): Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 5:584–590.

49. Jauhar S, Veronese M, Rogdaki M, Bloomfield M, Natesan S, Turkheimer F, et al. (2017): Regulation of dopaminergic function: An \textsuperscript{11}C-DOPA PET apomorphine challenge study in humans. Transl Psychiatry 7:e1027.

50. Hoshi H, Kucwabara H, Leger G, Cuming P, Guttmann M, Gjedde A (1993): \textsuperscript{6}-\textsuperscript{11}Cfluoro-L-DOPA metabolism in living human brain: A comparison of six analytical methods. J Cereb Blood Flow Metab 13:57–69.

51. Kumakura Y, Cuming P (2009): PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. Neuroscientist 15:635–650.

52. Jauhar S, Veronese M, Nour MM, Rogdaki M, Haddow P, Turkheimer FE, et al. (2018): Determinants of treatment response in first-episode psychosis: An \textsuperscript{18}F-DOPA PET study [published online ahead of print Apr 20]. Mol Psychiatry.

53. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, et al. (2009): Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-\textsuperscript{[11}C]DOPA: A stabilizing effect for dopaminergic neurotransmission? J Neurosci 29:13730–13734.

54. Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K, et al. (2012): Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-\textsuperscript{[11}C]DOPA. PLoS One 7:e46488.

55. Vernaleken I, Kumakura Y, Buchholz H-G, Siessmeier T, Hijgers R-D, Bartenstein P, et al. (2008): Baseline \textsuperscript{11}C-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage 40:1222–1231.
Effects of Antipsychotics on Dopamine Function in Psychosis

56. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. (1994): Input functions for 6-fluorine-18 fluorodopa quantitation in parkinsonism: Comparative studies and clinical correlations. J Nucl Med 35:955–963.

57. Holden JE, Doudet D, Endres CJ, Chan GL, Morrison KS, Vingerhoets FJ, et al. (1997): Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-o-methyltransferase. J Nucl Med 38:1568–1574.

58. Sossi V, Doudet DJ, Holden JE (2001): A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 21:469–476.

59. Ebdrup B, Nørbak H, Borgwardt S, Glenthøj B (2013): Volumetric changes in the basal ganglia after antipsychotic monotherapy: A systematic review. Curr Med Chem 20:438–447.

60. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD (2003): Psychosis prediction: 12-Month follow up of a high-risk (“prodromal”) group. Schizophr Res 60: 21–32.

61. Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, et al. (2015): Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry 173:69–77.

62. Goozée R, Handley R, Kempton MJ, Dazzan P (2014): A systematic review and meta-analysis of the effects of antipsychotic medications on regional cerebral blood flow (rCBF) in schizophrenia: Association with response to treatment. Neurosci Biobehav Rev 43:118–136.

63. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004): Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134–142.

64. Correll CU, Rubio JM, Kane JM (2018): What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17:149–160.